Effect of the glucagon‐like peptide‐1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes
Authors' conclusion
Although both liraglutide and CR are valuable strategies for cardiometabolic risk reduction, CR was associated with greater weight loss and more favourable improvements in body composition than treatment with liraglutide alone. Differences in the response to each of these interventions enables patients to be stratified to the most optimal intervention for their personal risk factors.
Study context
- Population
- Adults with obesity and prediabetes
- Participants
- 88 adults
- Comparison
- Liraglutide vs caloric restriction (CR) vs sitagliptin
- Primary endpoint
- Reduction in the proportion of fat to lean tissue mass
- Follow-up
- 14 weeks
Primary result
As reported in the abstract
Ratio of fat to lean mass, decrease
P = 0.02
Further findings
Weight loss ≥5% of baseline body weight · 14 weeks
Visceral fat reduction · 14 weeks
- Weight loss ≥5% of baseline body weight — P across groups
- p = 0.02
- Visceral fat reduction — P across groups
- p = 0.04
HOMA-IR
- Spontaneous reduction in dietary simple carbohydrates in CR associated with improved HOMA-IR
Original publication
Effect of the glucagon‐like peptide‐1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes. Diabetes Obes Metab. Published 15 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →